The Hive

The Hive is a hub of innovation. It’s a group of leading-edge biotech and pharmaceutical startups that are specially chosen, because of their impressive work in early-stage drug discovery & development, to further power their efforts with complimentary access to Elsevier’s suite of R&D solutions.

The Hive

Committed to promoting collaboration and inspiration across the Pharma & Life Sciences industry, The Hive is an opportunity for participating companies to accelerate their research and for others to learn from their experiences.

Joining the Hive

Our applications for 2020 are closed. If you want us to reach out when we reopen the Hive applications for 2021, please complete the form below.

Our ideal participants are start-ups or small companies that meet the following criteria:

Apply to the Hive

  • 10+ researchers focused on early-stage research
  • Eager to use our portfolio of products (ScienceDirect, Scopus, Embase, PharmaPendium, Text Mining, Reaxys and Reaxys Medicinal Chemistry)
  • Preferably, but not necessarily, pre-revenue and not actively seeking to be acquired in the next 18 months
  • Willing and excited to share their journey onboarding to Elsevier’s solutions with the world and to provide feedback to product development teams

Benefits for Hive participants include:

  • Free access to Elsevier’s solutions for pharma and life sciences
  • Training and support for solutions
  • Opportunities to help the shape the future of Elsevier’s products with product feedback
  • PR and exposure opportunities, including sharing stories of your research on our Pharma R&D blog

Benefits for Hive participants

Here is what Hive participants have had to say about their experience

"Access to Elsevier’s R&D Solutions’ suite of programs allows us to move our project forward. The Hive also gives hands-on training of technologies that will help us make better informed decisions on lead compound selections, and will increase our productivity by reducing the time we spend searching for relevant and trustworthy data for our research.“Claudia Bøen, CEO, Arctic Pharma



"A big R&D challenge for a small company developing a platform technology that can be broadly applied across multiple disease areas is the ability to rapidly get up to speed on different disease areas and other technical areas critical toward improving the technology. This includes understanding the science and biology as well as the IP, clinical, and commercial landscapes. But that’s what is great about being a part of the The Hive. Hive participation has been an amazing resource in support of our effort to address this challenge.“ Tom Wickham, Vice President Research and Development at Rubius Therapeutics
"The fact that we have rapid access to Elsevier journals and can use Reaxys to look for reaction conditions, if we have an idea in our 10 o’clock meeting, we may have the chemistry working by that same afternoon.“ Bruce Clapham, Director of Medicinal Chemistry, Reset Therapeutics


Hive Alumni

A diverse array of companies have been in the Hive, representing several countries and boasting a variety of approaches to cutting-edge drug discovery and development.

Arctic Pharma has a small team of scientists from around the globe working in their labs in Oslo, Norway to develop innovative anti-cancer drugs that don’t affect healthy cells, sparing patients the painful side effects of many typical treatments.

Rubius Therapeutics is harnessing the unique properties of red blood cells and genetic engineering to create a new class of cellular medicines aimed at treating rare enzyme deficiencies, cancer and autoimmune diseases.

Headquartered in France and focused on therapies for cancer and inflammatory diseases, 4P-Pharma bridges the gap between academic discoveries and the pharma industry, helping early-stage technologies mature to clinical phase and commercialization.

Exscientia, based in the UK, is the first company to automate drug design and is at the forefront of small molecule drug discovery. Using AI-driven systems, Exscientia has generated candidates in roughly one-quarter of the time of traditional approaches

Sigilon Therapeutics develops treatments based on a platform enabling a new therapeutic modality – immune-privileged living therapeutic implants – for chronic diseases and will soon be proceeding to human studies for their hemophilia A therapy.

Formerly known as Reset Therapeutics, Synchronicity Pharma leverages circadian rhythm biology research to treat a variety of diseases. Synchronicity developed the first-ever clinical stage compound shown to safely target the core-clock molecular machinery and to modulate clock-regulated gene expression in humans.

Berlin-based Myelo Therapeutics, which is developing innovative treatments in areas of high unmet medical need, has recently been granted Orphan Drug Designation for its chemical entity Myelo001 for the treatment of Acute Radiation Syndrome.

San Diego-based Beacon Discovery leverages academic and pharma partnerships to advance research around translating G-Protein Coupled Receptors (GPCRs) into new therapeutics.

LegoChem Biosciences, located in South Korea, utilizes its proprietary platform to develop next-gen Antibody-Drug Conjugates (ADC), providing solutions for site-specific conjugation, linker stability and efficient payload release—which are three major unmet needs in ADC development.

Unum Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products based on its universal Antibody-Coupled T-cell Receptor (ACTR), and they are currently testing product candidates in patients with lymphoma and multiple myeloma.